ABSTRACT
Corticosteroids play an important role in the therapeutic approach to vitreoretinal disease. The Ozurdex implant (DEX Implant 0.7 mg, Ozurdex, Allergan Inc., Irvine, CA, USA) offers sustained release of dexamethasone in the vitreous cavity, and this novel drug delivery system has proven useful both in improving clinical outcomes and in reducing injection burden. While the Food and Drug Administration approves the use of the DEX implant in retinal vein occlusions and non-infectious posterior uveitis, its utilization continues to expand in its breadth of diversity across myriad vitreoretinal conditions. Additionally, modified injection techniques are evolving to improve the safety profile of the DEX implant in eyes that are often considered to have relative contraindications to its use, further extending its application. This review aims to evaluate the evidence supporting the expanding indications and injection techniques of the DEX sustained-release implant in vitreoretinal disease, and explores potential future indications for its use. Arenas for future research are also identified to further elucidate the precise role of the DEX implant in our current treatment model. Increased awareness of effective and safe uses of the DEX implant can refine our therapeutic approach to vitreoretinal disease and ultimately improve patient outcomes.
Subject(s)
Dexamethasone/administration & dosage , Drug Implants , Eye Diseases/drug therapy , Glucocorticoids/administration & dosage , Retinal Diseases/drug therapy , Vitreous Body/drug effects , Absorbable Implants , Drug Delivery Systems , Humans , Intravitreal InjectionsABSTRACT
INTRODUCTION: The anatomic localization of reticular pseudodrusen (RPD) has been an important area of research study. METHODS: A multimodal imaging analysis was conducted of two patients who were classified as having presumed RPD. RESULTS: Analysis of case 1 lends credence to original histopathologic evidence suggesting a choroidal origin of RPD, and analysis of case 2 supports RPD as originating above the RPE. CONCLUSION: This case series demonstrates that RPD may represent a compilation of diseases rather than one distinct clinical entity.
Subject(s)
Multimodal Imaging , Retinal Drusen/diagnosis , Aged , Female , HumansABSTRACT
PURPOSE: To investigate the role of silicone oil as an adjunct to iodine 125 ((125)I) brachytherapy in attenuating radiation dose and reducing radiation retinopathy. METHODS: A 16-mm COMS plaque loaded with (125)I seeds was simulated in vitro on an eye model containing silicone oil as a vitreous substitute using BrachyDose. The radiation dose ratio of silicone oil vs water to ocular structures was calculated at angles subtended from the centre of the eye. Silicone oil was then used in three choroidal melanoma patients who underwent 23-gauge vitrectomy, silicone oil placement, and (125)I brachytherapy. RESULTS: Silicone oil reduced the ocular radiation dose in vitro to 65%. Radiation dose ratios on the retina increased from 0.45 to 0.99 when moving from points diametrically opposed to the plaque's central axis. In 10-24 months' follow-up, no patients have developed radiation retinopathy. Each patient required silicone oil removal and experienced cataract progression, and one also developed a retinal detachment. CONCLUSIONS: This study confirms that silicone oil attenuates radiation dose in vitro, and may protect against radiation retinopathy clinically in patients, however it requires extensive surgical interventions. Further studies in only very selected populations using silicone oil as an adjunct to (125)I brachytherapy will best elucidate its role in shielding radiation retinopathy.
Subject(s)
Brachytherapy/methods , Choroid Neoplasms/radiotherapy , Endotamponade , Iodine Radioisotopes/therapeutic use , Melanoma/radiotherapy , Radiation Injuries/prevention & control , Radiation-Protective Agents/therapeutic use , Retina/radiation effects , Silicone Oils , Aged , Drainage , Female , Humans , Middle Aged , Radiotherapy Dosage , VitrectomySubject(s)
Obesity/complications , Obesity/epidemiology , Pseudotumor Cerebri/etiology , Female , Humans , MaleABSTRACT
Warfarin sodium has been associated with leucocytoclastic vasculitis and has once been associated with allergic interstitial nephritis. Hypersensitivity to warfarin sodium simultaneously resulting in allergic interstitial nephritis and leucocytoclastic vasculitis has not yet been previously reported. We present a 48-year-old man who was on warfarin sodium for 2 months and presented with acute renal failure and reddish purplish macules on his hypogastric regions and lower extremities bilaterally. Kidney biopsy showed allergic interstitial nephritis and punch skin biopsy showed leucocytoclastic vasculitis. Both biopsies also showed high eosinophil count, highly suggestive of a drug-induced reaction. After a negative comprehensive work-up and the absence of other recent medication changes, our patient was determined to have allergic interstitial nephritis and leucocytoclastic vasculitis secondary to warfarin sodium.
